Sarepta cut to Neutral at Citi on risks to valuation [Seeking Alpha]
Catalent, Inc. (CTLT)
Last catalent, inc. earnings: 2/3 07:30 am
Check Earnings Report
US:NYSE Investor Relations:
investor.catalent.com
Company Research
Source: Seeking Alpha
to trade lower in the premarket Wednesday as Citi downgraded the stock based on valuation. The shares of the Cambridge, Massachusetts-based biotech surged more than 30% on Friday after the FDA label expansion for gene therapy targeted at Duchenne muscular dystrophy (DMD) exceeded Wall Street's expectations. Elevidys is marketed by Sarepta ( SRPT ) in partnership with Roche ( OTCQX:RHHBY OTCQX:RHHBF ), with manufacturing support from Catalent ( CTLT However, with SRPT shares up more than a third over the past five days, Citi analyst David Hoang downgraded the stock to Neutral from Buy, citing risks to the valuation. "We see high expectations reflected in consensus numbers, where any volatility in the early launch could translate to downside, given what is now baked into the valuation," Hoang wrote, noting a fair value of no more than $180 per share for the stock. However, Citi raised its price target on SRPT to $176 from $172 per share following minor adjustments to its Elevi
Show less
Read more
Impact Snapshot
Event Time:
CTLT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CTLT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CTLT alerts
High impacting Catalent, Inc. news events
Weekly update
A roundup of the hottest topics
CTLT
News
- Catalent, Inc. (NYSE: CTLT) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Catalent, Inc. (NYSE: CTLT) was downgraded by analysts at Baird R W from a "strong-buy" rating to a "hold" rating.MarketBeat
- Catalent cut to neutral at Baird as analyst unable to find valuation in a deal break [Seeking Alpha]Seeking Alpha
- Catalent, Inc. (NYSE: CTLT) had its "neutral" rating re-affirmed by analysts at Robert W. Baird. They now have a $63.50 price target on the stock.MarketBeat
- Asia-Pacific CDMO Market Share Analysis, Industry Trends & Growth Forecasts 2024-2029: Demand For Injectable Dose Formulation is Rising in the Market [Yahoo! Finance]Yahoo! Finance
CTLT
Earnings
- 8/29/24 - Miss
CTLT
Sec Filings
- 9/27/24 - Form 4
- 9/26/24 - Form 144
- 9/6/24 - Form 10-K
- CTLT's page on the SEC website